ObsEva SA (OBSV)
| Market Cap | 25.86M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -50.17M |
| Shares Out | 83.70M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,329,132 |
| Open | 0.332 |
| Previous Close | 0.340 |
| Day's Range | 0.286 - 0.332 |
| 52-Week Range | 0.222 - 3.350 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 6.43 (+1,980.9%) |
| Earnings Date | Aug 8, 2022 |
About OBSV
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a recepto... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for OBSV stock is "Buy." The 12-month stock price forecast is 6.43, which is an increase of 1,980.91% from the latest price.
News
All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy
ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva Announces Management Change
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
Why Is ObsEva (OBSV) Stock Down 70% Today?
Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press release early this morning.
ObsEva Announces Corporate Updates
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment...
Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy
ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids
ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for t...
- Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy -
Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for...
LONDON--(BUSINESS WIRE)--The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses
-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20 th Wo...
ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
GENEVA, Switzerland May 1 9 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment o...
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18,...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update
-Linzagolix for uterine fibroids: Received c onfirmation of p ositive CHMP opinion for marketing authorization application ; United States NDA PDUFA date in Q3:22 -
ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
GENEVA, Switzerland May 1 6 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Company Mana...
ObsEva to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
GENEVA, Switzerland – May 1 2 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans t...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 AC...
- Additional data from the PRIMROSE Phase 3 stud ies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15 am PT/12:15 pm ET-
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva Annual General Meeting 2022
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva Annual Report 2021
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg w...
-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of treatment, respectivel...
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion-
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
- Partnership leverages Theramex's leading women's health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix across global markets outside ...